
Keywords: فسفودی استراز 4; atopic dermatitis; crisaborole; eczema; long-term safety; ointment; PDE4; phosphodiesterase-4; topical treatment; AD; atopic dermatitis; AE; adverse event; ISGA; Investigator's Static Global Assessment; PDE4; phosphodiesterase-4; SAE; serious adverse even